Private company

Repare Therapeutics Inc.

In its 2025 annual report the company says: “We are a clinical-stage precision oncology company enabled by our proprietary synthetic lethality approach to the discovery and development of novel therapeutics. We use our proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies that preferentially treat cancers due to mechanisms of genomic instability, including DNA damage repair.”3 It is headquartered in Saint-Laurent, Canada.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersSaint-Laurent, Canada1
  • Incorporated inCanada (Federal Level)2
  • Business address7171 Frederick Banting, Suite 270, Building 2, Saint-Laurent, A8 H4S 1Z92
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

We are a clinical-stage precision oncology company enabled by our proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Synthetic lethality (SL) represents a clinically validated approach to drug development. We use our proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies that preferentially treat cancers due to mechanisms of genomic instability, including DNA damage repair. SL arises when a deficiency in either of two genes is tolerated in cells, but simultaneous deficiencies in both genes cause cell death. Cancer cells that contain a mutation in one gene of a SL pair are susceptible to therapeutic intervention targeting the other gene pair.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income4567-$93.5M in 2024+255% since 2019
-$150.0M-$100.0M-$50.0M02019: -$26.4M-$26.4M20192020: -$54.3M-$54.3M2020+106%2021: -$108.7M-$108.7M2021+100%2022: -$19.8M-$19.8M2022−82%2023: -$116.2M-$116.2M2023+487%2024: -$93.5M-$93.5M2024−20%
Net income4567-$84.7M in 2024+211% since 2019
-$150.0M-$100.0M-$50.0M02019: -$27.2M-$27.2M20192020: -$53.4M-$53.4M2020+96%2021: -$106.9M-$106.9M2021+100%2022: -$29.0M-$29.0M2022−73%2023: -$93.8M-$93.8M2023+223%2024: -$84.7M-$84.7M2024−10%
Fiscal year20182019202020212022202320242025
Research and development$21.0M4$40.1M4$90.0M5$119.1M6$133.6M7$115.9M7
Operating expenses$116.3M5$151.6M6$167.4M7$147.0M7
Operating income-$26.4M4-$54.3M4-$108.7M5-$19.8M6-$116.2M7-$93.5M7
Income before tax-$108.6M5-$13.9M6-$103.2M7-$83.2M7
Income tax$195.0K4-$1.3M4-$1.7M5$15.1M6-$9.4M7$1.4M7
Net income-$27.2M4-$53.4M4-$106.9M5-$29.0M6-$93.8M7-$84.7M7
Earnings per share-$2.835-$0.696-$2.237-$2.007
Earnings per share (diluted)-$2.835-$0.696-$2.237-$2.007
Shares (weighted, basic)37.8M shares541.9M shares642.1M shares742.4M shares7
Shares (weighted, diluted)37.8M shares541.9M shares642.1M shares742.4M shares7

Compare Repare Therapeutics Inc. with another company

Corporate structure

Repare Therapeutics Inc. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Repare Therapeutics Inc.

  • Blue Owl Capital Filed SCHEDULE 13G/A on Repare Therapeutics Inc., latest May 14, 2026 (3 filings since Feb 14, 2024)
  • BIOTECHNOLOGY VALUE FUND L P Filed SCHEDULE 13D/A on Repare Therapeutics Inc., latest Jan 30, 2026 (7 filings since Feb 14, 2022)
  • Shay Capital LLC Filed SCHEDULE 13G on Repare Therapeutics Inc., latest Jan 27, 2026
  • Versant Venture Capital V, L.P. Filed SCHEDULE 13D/A on Repare Therapeutics Inc., latest Nov 21, 2025 (3 filings since Jun 13, 2022)
  • ARK Investment Management LLC Filed SCHEDULE 13G/A on Repare Therapeutics Inc., latest Feb 14, 2025 (4 filings since Feb 9, 2022)
  • MPM BioVentures 2014, L.P. Filed SCHEDULE 13D/A on Repare Therapeutics Inc., latest Jan 31, 2025 (4 filings since Dec 26, 2024)
  • Deep Track Capital, LP Filed SC 13G/A on Repare Therapeutics Inc., latest Nov 14, 2024 (5 filings since Oct 29, 2021)
  • Redmile Group, LLC Filed SC 13G/A on Repare Therapeutics Inc., latest Nov 14, 2024 (4 filings since Feb 14, 2022)
  • PRICE T ROWE ASSOCIATES INC /MD/ Filed SC 13G/A on Repare Therapeutics Inc., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
  • CHI Advisors LLC Filed SC 13G/A on Repare Therapeutics Inc., latest Feb 13, 2023 (2 filings since Feb 11, 2022)
  • FMR LLC Filed SC 13G/A on Repare Therapeutics Inc., latest Feb 9, 2023 (2 filings since Feb 9, 2022)
  • ORBIMED ADVISORS LLC Filed SC 13D/A on Repare Therapeutics Inc., latest Nov 2, 2021
  • Repare Therapeutics Inc. Saint-Laurent, Canada

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Repare Therapeutics Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$11.5M7 Dec 31, 2024$11.5M7 Dec 31, 2023−0.2%
Accumulated depreciation$9.2M7 Dec 31, 2024$7.3M7 Dec 31, 2023+26.0%
Property and equipment, net$2.3M7 Dec 31, 2024$4.2M7 Dec 31, 2023−45.6%
Operating-lease assets (leased space)$1.9M7 Dec 31, 2024$3.3M7 Dec 31, 2023−42.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$84.7M7 Dec 31, 2024$111.3M7 Dec 31, 2023−23.9%
Marketable securities, current$68.1M7 Dec 31, 2024$112.4M7 Dec 31, 2023−39.4%

Properties, in its own words

Our headquarters is currently located in Montréal, Québec, Canada and consists of 24,039 square feet of combined laboratory and office space under a lease agreement that expires in August 2025. This facility provides the laboratory capacity for our CRISPR-enabled genome-wide synthetic lethal target platform, SNIPRx®, including dedicated space for work related to accelerating our preclinical assets. We also lease 11,312 square feet of office space in Cambridge, Massachusetts for our U.S.-based employees under a lease which expires in January 2026. In line with the announced realignment of resources and strategic reprioritization of our research and development activities to focus our efforts on the advancement of our Phase 1 clinical programs, RP-3467 and RP-1664, we are currently exploring our lease options.

Item 2 of the 10-K filed Mar 3, 2025.3

Leadership

Who has led Repare Therapeutics Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Lloyd Mitchell Segal2020–now

President

  1. Lloyd Mitchell Segal2020–now
2025
Board members and other officers (13)

Timeline

  1. Jan 28, 20268-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights25
  2. Jan 16, 20268-K Shareholder vote; Regulation FD disclosure26
  3. Dec 29, 20258-K Entered a material agreement; Completed an acquisition or sale; Regulation FD disclosure27
  4. Dec 19, 20258-K Executive or director change28
  5. Nov 17, 20258-K Entered a material agreement29
  6. Nov 14, 20258-K Results of operations; Other events30
  7. Oct 22, 20258-K Regulation FD disclosure31
  8. Aug 8, 20258-K Results of operations32
  9. Jul 16, 20258-K Entered a material agreement; Regulation FD disclosure33
  10. Jun 20, 20258-K Executive or director change34
  11. Jun 17, 20258-K Shareholder vote35
  12. Jun 2, 20258-K Executive or director change36
  13. Jun 18, 2020New chief executive Lloyd Mitchell Segal becomes CEO11

Calendar

When it reported results

  1. Nov 14, 2025Reported quarterly or annual results30
  2. Aug 8, 2025Reported quarterly or annual results32
  3. May 13, 2025Reported quarterly or annual results37
  4. Mar 3, 2025Reported quarterly or annual results38
  5. Jan 10, 2025Reported quarterly or annual results39
  6. Nov 7, 2024Reported quarterly or annual results40
  7. Aug 6, 2024Reported quarterly or annual results41
  8. May 7, 2024Reported quarterly or annual results42

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

248 filings to the SEC since October 2021: 4 annual reports, 13 quarterly reports, 54 major events, 84 insider forms, 38 large holders, 55 other. The latest 20:

  1. May 14, 2026SCHEDULE 13G/A EDGAR
  2. Feb 19, 202615-12G EDGAR
  3. Jan 30, 2026EFFECT EDGAR
  4. Jan 30, 20264 OWNERSHIP DOCUMENT EDGAR
  5. Jan 30, 2026SCHEDULE 13D/A EDGAR
  6. Jan 28, 20264 EDGAR
  7. Jan 28, 20264 EDGAR
  8. Jan 28, 20264 EDGAR
  9. Jan 28, 20264 EDGAR
  10. Jan 28, 20264 EDGAR
  11. Jan 28, 2026S-8 POS EDGAR
  12. Jan 28, 2026S-8 POS EDGAR
  13. Jan 28, 2026S-8 POS EDGAR
  14. Jan 28, 2026S-8 POS EDGAR
  15. Jan 28, 2026S-8 POS EDGAR
  16. Jan 28, 2026S-8 POS EDGAR
  17. Jan 28, 2026S-8 POS EDGAR
  18. Jan 28, 2026S-8 POS EDGAR
  19. Jan 28, 2026POS AM EDGAR
  20. Jan 28, 20268-K EDGAR

The 248 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

43 open-market trades by officers, directors and large owners since October 2021: 10 buys and 33 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 12, 2025Koehler MariaEVP, CHIEF MEDICAL OFFICERSale3,596$1.14$4.1KForm 4
Mar 12, 2025Zinda MichaelEVP, CHIEF SCIENTIFIC OFFICERSale5,611$1.14$6.4KForm 4
Mar 12, 2025Forte SteveEVP, CHIEF FINANCIAL OFFICERSale6,884$1.14$7.8KForm 4
Mar 12, 2025Segal Lloyd MitchellPRESIDENT AND CEOSale21,179$1.14$24.1KForm 4
Apr 1, 2024Segal Lloyd MitchellPRESIDENT AND CEOSale2,491$4.63$11.5KForm 4
Apr 1, 2024Forte SteveEVP, CHIEF FINANCIAL OFFICERSale789$4.61$3.6KForm 4
Apr 1, 2024Zinda MichaelEVP, CHIEF SCIENTIFIC OFFICERSale410$4.66$1.9KForm 4
Apr 1, 2024Koehler MariaEVP, CHIEF MEDICAL OFFICERSale300$4.66$1.4KForm 4
Mar 28, 2024Segal Lloyd MitchellPRESIDENT AND CEOSale2,650$4.62$12.2KForm 4
Mar 28, 2024Forte SteveEVP, CHIEF FINANCIAL OFFICERSale825$4.62$3.8KForm 4
Mar 28, 2024Zinda MichaelEVP, CHIEF SCIENTIFIC OFFICERSale450$4.64$2.1KForm 4
Mar 28, 2024Koehler MariaEVP, CHIEF MEDICAL OFFICERSale500$4.64$2.3KForm 4
Mar 27, 2024Forte SteveEVP, CHIEF FINANCIAL OFFICERSale825$4.62$3.8KForm 4
Mar 27, 2024Zinda MichaelEVP, CHIEF SCIENTIFIC OFFICERSale450$4.62$2.1KForm 4
Mar 27, 2024Koehler MariaEVP, CHIEF MEDICAL OFFICERSale500$4.62$2.3KForm 4
Mar 27, 2024Segal Lloyd MitchellPRESIDENT AND CEOSale2,650$4.63$12.3KForm 4
Mar 26, 2024Forte SteveEVP, CHIEF FINANCIAL OFFICERSale825$4.60$3.8KForm 4
Mar 26, 2024Zinda MichaelEVP, CHIEF SCIENTIFIC OFFICERSale450$4.61$2.1KForm 4
Mar 26, 2024Koehler MariaEVP, CHIEF MEDICAL OFFICERSale500$4.60$2.3KForm 4
Mar 26, 2024Segal Lloyd MitchellPRESIDENT AND CEOSale2,650$4.64$12.3KForm 4

All 43 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2024Lloyd M. Segal$630.5K$2.4M55
2024Maria KoehlerM.D., Ph.D.$505.0K$1.2M55
2024Michael ZindaPh.D.$474.5K$1.2M55
2023Former President and Chief Executive Officer$615.0K$5.0M55
2023Former Executive Vice PresidentChief Medical Officer$493.5K$2.1M55
2023Executive Vice PresidentChief Scientific Officer$463.0K$1.8M55

SEC filer profile

How Repare Therapeutics Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARRepare Therapeutics Inc.1
  • CIK0001808158
  • Employer ID (EIN)00-00000003
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inA83
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address7171 Frederick Banting, Suite 270, Building 2, Saint-Laurent, A8 H4S 1Z91
  • Phone(857) 412-70181
  • Shares outstanding42,985,755 as of Oct 31, 20259
  • Public float$129.0M as of Jun 30, 20243
  • AuditorErnst & Young LLP, Montréal, Canada PCAOB ID 1263; it also attests to the company’s internal control over financial reporting3
  • On EDGAR sinceApr 6, 20201
  • Filings424 in all: 4 (180), 8-K (62), 3 (22), SC 13G/A (21), 10-Q (17), DEFA14A (11), SC 13D/A (10), S-8 (8)1
    All 43 form types

    S-8 POS (8), SC 13G (8), 144 (7), SCHEDULE 13D/A (7), CORRESP (6), 10-K (5), DEF 14A (5), 424B5 (4), EFFECT (4), SC 13D (4), UPLOAD (4), ARS (3), POS AM (3), FWP (2), S-1/A (2), SCHEDULE 13G/A (2), 15-12G (1), 25-NSE (1), 3/A (1), 4/A (1), 424B4 (1), 8-A12B (1), 8-K/A (1), CERT (1), DEFM14A (1), DRS (1), DRS/A (1), DRSLTR (1), POSASR (1), PREM14A (1), S-1 (1), S-1MEF (1), S-3 (1), S-3ASR (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Mar 3, 2025
    Quarterly report (10-Q) Nov 14, 2025
    Proxy statement (DEF 14A) Apr 29, 2025
    Latest 8-K (8-K) Jan 28, 2026

Securities registered for trading

ClassSymbolExchange
Common Shares, no par valueRPTXThe Nasdaq Stock Market LLC

From the cover page of the 10-K filed Mar 3, 2025 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks Repare Therapeutics Inc. names in Item 1A of its 10-K filed Mar 3, 2025: 71 risks under these headings, as written.3

  • Risks Related to Our Re-Prioritization and Strategic Review Process
  • Our corporate restructuring and the associated headcount reduction may not result in anticipated savings, could result in total costs and expenses that are greater than expected, could disrupt our business and could affect our ability to retain the employees required to consummate a strategic transaction.
  • Risks Related to Our Financial Position and Capital Needs
  • Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
  • We have incurred significant operating losses since inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability.
  • We will require substantial additional funding to finance our operations. If we are unable to raise capital when needed, we could be forced to delay, reduce, or terminate certain of our product development programs or other operations.
  • Raising additional capital will cause dilution to our shareholders, restrict our operations, or require us to relinquish rights to our product candidates.
  • Risks Related to the Development of Our Product Candidates
  • We are very early in our development efforts. If we are unable to advance our product candidates into and through clinical development, obtain regulatory approval and ultimately commercialize any of our product candidates, or experience significant delays in doing so, our business will be materially harmed.
  • We may not be able to file INDs or IND amendments to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.
  • The successful development of targeted therapeutics, including our portfolio of SL small molecule inhibitors, as well as any related diagnostics, is highly uncertain.
  • We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
The other 62 risks
  • Clinical trials are very expensive, time consuming and difficult to design and implement.
  • Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials and we cannot assure you that any ongoing, planned or future clinical trials will lead to results sufficient for the necessary regulatory approvals.
  • Interim, “top-line” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, on a timely basis or at all, our business will be substantially harmed.
  • Synthetic lethality represents an emerging class of precision medicine targets, and negative perceptions of the efficacy, safety, or tolerability of this class of targets, including any that we develop, could adversely affect our ability to conduct our business, advance our product candidates or obtain regulatory approvals.
  • Difficulty in enrolling patients could delay or prevent clinical trials of our product candidates. We may find it difficult to enroll patients in our ongoing and planned clinical trials with the genomic alterations that these trials are designed to target.
  • Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.
  • We conduct clinical trials for product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.
  • If it is determined that companion diagnostics are needed, we may be unable to successfully develop companion diagnostics for biomarkers that enable patient selection, or experience significant delays in doing so, we may not realize the full commercial potential of our product candidates.
  • The failure to obtain required regulatory approvals for any companion diagnostic tests that may be required and that we may pursue may prevent or delay approval of our product candidates. Moreover, the commercial success of any of our product candidates may be tied to the regulatory approval, market acceptance and continued availability of a companion diagnostic.
  • We intend to pursue the development of certain of our product candidates in combination with other therapies, and regulatory approval, safety or supply issues with these other therapies may delay or prevent the development and approval of our product candidates.
  • Risks Related to the Commercialization of Our Product Candidates
  • We have never commercialized a product candidate and may experience delays or unexpected difficulties in obtaining regulatory approval for our current or future product candidates for our initial or potential additional indications.
  • We currently have no marketing and sales organization and have no experience as a company in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, if approved, we may not be able to generate product revenue.
  • Due to our limited resources and access to capital, we must, and have in the past decided to, prioritize development of certain product candidates over other potential product candidates. These decisions may prove to have been wrong and may adversely affect our ability to develop our own programs, our attractiveness as a commercial partner and may ultimately have an impact on our commercial success.
  • Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community.
  • The market opportunities for our product candidates may be relatively small as it will be limited to those patients who are ineligible for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate.
  • We face substantial competition, which may result in others developing or commercializing drugs before or more successfully than us.
  • If we obtain approval to commercialize any products outside of the United States, a variety of risks associated with international operations could adversely affect our business.
  • Coverage and adequate reimbursement may not be available for our product candidates, which could make it difficult for us to sell profitably or at all, if approved.
  • We may become exposed to costly and damaging liability claims, either when testing our product candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims.
  • Risks Related to Regulatory Matters
  • Even if we obtain FDA approval for any of our product candidates in the United States, we may never obtain approval for or commercialize any of them in any other jurisdiction, which would limit our ability to realize their full market potential.
  • Even if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.
  • Our relationships with customers, physicians, and third-party payors are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, transparency, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
  • Enacted and future healthcare legislation may increase the difficulty and cost for us to progress our clinical programs and obtain marketing approval of and commercialize our product candidates and may affect the prices we may set.
  • We may face potential liability if we obtain identifiable patient health information from clinical trials sponsored by us.
  • If we or our third-party manufacturers and suppliers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.
  • We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.
  • Risks Related to Our Dependence on Third Parties
  • We rely, and expect to continue to rely, on third parties, including independent clinical investigators, contracted laboratories and CROs, to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.
  • We rely on third parties to supply and manufacture our product candidates, and we expect to continue to rely on third parties to manufacture our products, if approved. The development of such product candidates and the commercialization of any products, if approved, could be stopped, delayed, or made less profitable if any such third party fails to provide us with sufficient quantities of product candidates or products or fails to do so at acceptable quality levels or prices or fails to maintain or achieve satisfactory regulatory compliance.
  • Our current and future collaborations will be important to our business. If we are unable to enter into new collaborations as appropriate, or if these collaborations are not successful, our business could be adversely affected.
  • Risks Related to Our Intellectual Property
  • Our success depends in part on our ability to obtain intellectual property rights for our proprietary technologies and product candidates, as well as our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • We rely in part on trade secrets to protect our technology, and our failure to obtain or maintain trade secret protection could harm our business.
  • Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
  • Intellectual property rights do not necessarily address all potential threats to our business.
  • We may become involved in lawsuits to protect or enforce our patents or other intellectual property rights, which could be expensive, time consuming and unsuccessful.
  • Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business.
  • We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.
  • We depend on intellectual property licensed from a third party and termination of this license could result in the loss of significant rights, which would harm our business.
  • We may be subject to claims asserting that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.
  • Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our future product candidates.
  • We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.
  • Reliance on third parties requires us to share our proprietary information, which increases the possibility that such information will be misappropriated or disclosed.
  • Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business.
  • If we are unable to protect the confidentiality of our proprietary information, our business and competitive position would be harmed.
  • If we do not obtain patent term extension for patents covering our product candidates, our business may be materially harmed, and in any case, the terms of our patents may not be sufficient to effectively protect our product candidates and business.
  • Risks Related to Our Business Operations, Employee Matters and Managing Growth
  • Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
  • Our internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a significant disruption of our product development programs and our ability to operate our business effectively.
  • Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.
  • Our international operations pose currency risks, which may adversely affect our operating results.
  • Failure to comply with health and data protection laws and regulations could lead to government enforcement actions, including civil or criminal penalties, private litigation, and adverse publicity and could negatively affect our operating results and business.
  • Data collection is governed by restrictive regulations governing the use, processing, and cross-border transfer of personal information.
  • Our employees, principal investigators, consultants, and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.
  • Risks Related to Ownership of Our Common Shares
  • We are a “smaller reporting company” and we cannot be certain if the reduced reporting requirements applicable to smaller reporting companies will make our common shares less attractive to investors.
  • The trading price of our common shares has been and is likely to continue to be volatile and fluctuate substantially.
  • Concentration of ownership of our common shares among our existing executive officers, directors and principal shareholders may prevent new investors from influencing significant corporate decisions.
  • If research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our share price and trading volume could decline.
  • The sale of a substantial number of our common shares in the public market could cause the market price of our shares to drop significantly, even if our business is doing well.
  • Because we do not anticipate paying any cash dividends on our share capital in the foreseeable future, capital appreciation, if any, will be your sole source of gain.
  • Our articles of continuance permit us to issue an unlimited number of common shares and preferred shares without additional shareholder approval.
  • If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common shares.
  • Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.

Legal proceedings

From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have an adverse effect on our business, operating results or financial condition.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55